Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer.

about

Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer.

Item

http://www.wikidata.org/entity/Q48518084

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Sensitive and specific assessm ...... in platelet function analyzer.

@en

Sensitive and specific assessm ...... in platelet function analyzer.

@nl

type

Item

label

Sensitive and specific assessm ...... in platelet function analyzer.

@en

Sensitive and specific assessm ...... in platelet function analyzer.

@nl

prefLabel

Sensitive and specific assessm ...... in platelet function analyzer.

@en

Sensitive and specific assessm ...... in platelet function analyzer.

@nl

P1476

Sensitive and specific assessm ...... in platelet function analyzer.

@en

P2093

Aaron R Novack

http://www.w3.org/2001/XMLSchema#string

Helmut W Ott

http://www.w3.org/2001/XMLSchema#string

Isabell Pekrul

http://www.w3.org/2001/XMLSchema#string

Michael Spannagl

http://www.w3.org/2001/XMLSchema#string

Peter L Turecek

http://www.w3.org/2001/XMLSchema#string

Thorsten Kragh

http://www.w3.org/2001/XMLSchema#string

P2860

Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers.

Acquired von Willebrand syndrome in aortic stenosis.

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

Clinical utility of the PFA-100.

Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09537104.2017.1420153

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29319374

http://www.w3.org/2001/XMLSchema#string